Patent counselling specialist Mark Hayman has joined Bingham McCutchen LLP’s Boston office as a partner.
New York-headquartered Forest Laboratories has filed suit against Indian company Aurobindo Pharma to protect Namenda, a treatment for moderate to severe Alzheimer’s disease.
IP legislation in the United Arab Emirates is among the strongest in the region but the courts have had so few issues to handle that the country’s lawyers and judges may not yet be well equipped to deal with biotech cases.
Patent rejections based on 35 USC §101, which relate to patent eligibility, are “incredibly case-specific”, making it difficult to identify trends or draw broad conclusions, said Matthew McFarlane, a partner at Robins, Kaplan, Miller & Ciresi LLP at the BIO International Convention yesterday.
An increasing trend among scientists to want to put their new ideas into the public domain to be shared for the benefit of all is putting research bodies that rely on partnerships with industry for a substantial proportion of their income at risk, according to Jean Derégnaucourt, executive vice-president for business development at the Institut Pasteur in Paris.
In a discussion about the implications of the US Supreme Court’s decisions on patent-eligible matter in Prometheus and Myriad at the BIO International Convention yesterday, entitled Patent eligibility from the trenches, an audience member expressed concern that uncertainty over patenting rules could drive American innovators overseas.
Learning to determine the value technological advance has contributed requires a great degree of sophistication, Randall Rader said in a session on protecting biotechnology innovations in the US and Latin America at the 2014 BIO International Convention in San Diego, California, yesterday (Tuesday).
The whole international patent community has been reasonably good at developing new patent laws but hopeless at compliance, said Francis Gurry, director general of the World Intellectual Property Organization.
The American public's access to new and effective medicines could be at risk as a result of the US Supreme Court's decisions in the Prometheus and Myriad cases, and the resulting guidance for examiners from the USPTO, according to a report presented to the 2014 BIO International Convention in San Diego today.
The Indian Patent Office has rejected a patent application for an anti-cancer drug for the second time, paving the way for generic versions to potentially enter the market.